Patents by Inventor Sita Kugel

Sita Kugel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20220152081
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: September 8, 2021
    Publication date: May 19, 2022
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20210030781
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: March 16, 2020
    Publication date: February 4, 2021
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • Agents and methods for treating pancreatic ductal adenocarcinomas
    Patent number: 10588920
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 17, 2020
    Assignee: The General Hospital Corporation
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20180085389
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by con trolling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 29, 2018
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar